The International Journal of Neuropsychopharmacology

Letter to the Editor

Case series on the use of aripiprazole for Tourette syndrome

Tanya K. Murphy a1c1, Michael A. Bengtson a1a2, Ohel Soto a1, Paula J. Edge a1, Muhammad W. Sajid a1, Nathan Shapira a1 and Mark Yang a3
a1 Department of Psychiatry, University of Florida, Gainesville, FL, USA
a2 Department of Psychiatry, North Florida South Georgia Veteran's Health System, University of Florida, Gainesville, FL, USA
a3 Department of Statistics, University of Florida, Gainesville, FL, USA

Article author query
murphy tk   [PubMed][Google Scholar] 
bengtson ma   [PubMed][Google Scholar] 
soto o   [PubMed][Google Scholar] 
edge pj   [PubMed][Google Scholar] 
sajid mw   [PubMed][Google Scholar] 
shapira n   [PubMed][Google Scholar] 
yang m   [PubMed][Google Scholar] 

Characterized by multiple motor and phonic tics, Tourette syndrome (TS) is also associated with a constellation of comorbid disorders, including obsessive–compulsive symptoms that occur in 40–60% of patients. The pathophysiology of tics has been linked by many studies to specific cortical and basal ganglia changes and hypothesized to relate to dysregulation of dopamine responsive/dependent circuits (Jordan et al., 2004). Aripiprazole, a recently released atypical antipsychotic noted for its partial D2 agonist activity along with a low propensity for extrapyramidal effects, has been shown to be efficacious in reducing symptoms of schizophrenia in adults. The value of aripiprazole for treating neuropsychiatric disorders in children has not previously been reported. We present results of a retrospective chart review of six youth with TS and comorbid obsessive–compulsive disorder (OCD) who were treated for 12 wk with aripiprazole.

(Received November 11 2004)
(Reviewed December 7 2004)
(Revised December 12 2004)
(Accepted December 19 2004)

c1 Department of Psychiatry, Box 100256, University of Florida, Gainesville, FL, 32610, USA. Tel.: 352-392-3681 (assistant: 352-294-0418) Fax: 352-392-2579 E-mail: